Premium
The Bruton’s tyrosine kinase inhibitor ibrutinib abrogates bispecific antibody‐mediated T‐cell cytotoxicity
Author(s) -
Godwin Colin D.,
Bates Olivia M.,
Garling Eliotte E.,
Beddoe Mary E.,
Laszlo George S.,
Walter Roland B.
Publication year - 2020
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.16406
Subject(s) - ibrutinib , bruton's tyrosine kinase , cytotoxicity , tyrosine kinase , cancer research , tyrosine kinase inhibitor , chemistry , antibody , medicine , pharmacology , leukemia , immunology , signal transduction , biochemistry , chronic lymphocytic leukemia , cancer , in vitro
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom